Developer docs
API playgroundTry for free, no card

Search company profiles

Risklick

Full company profile

uuid0006xgd

Namestring
Risklick
Legal namestring
Risklick AG
Websiteurl
risklick.ch
Company typeenum
Private
Founded yearint
2019
Descriptiontext

Risklick AG is a Swiss AI company founded in 2019 and headquartered in Bern that develops Protocol AI, an enterprise SaaS platform for designing and authoring clinical trial protocols and study plans. The platform is powered by a proprietary database of over 800,000 clinical trials linked to publications, regulatory approvals, and safety data, and uses customized generative AI to produce protocols in ICH M11 and USDM-standard digital formats with export options for Word, Excel, or JSON. It integrates directly with EDC and eTMF systems and follows a structured three-step workflow (Explore, Design, Develop) for evidence-based study design optimization.

The company targets pharmaceutical sponsors as its primary segment and life sciences organizations (CROs and biotech companies) as a secondary segment, selling through enterprise direct sales with "Request a Demo" CTAs and annual subscription plans with tiered user roles (Organization Admin, Creator, Reviewer, Reader). Pricing is quote-based and not publicly disclosed. A secondary product, Deduklick, offers AI-powered automated data deduplication as an add-on. Strategic distribution is augmented by a January 2026 partnership with Citeline, and the company holds ISO 27001:2022 certification and GDPR compliance posture.

Risklick is privately held, backed by Debiopharm Innovation Fund since April 2024, and has received the Innosuisse Certificate recognizing growth readiness in the second half of 2025. Stated outcome metrics include a 50% reduction in protocol development time, 20% reduction in protocol amendments, and 40% reduction in protocol implementation time, though these figures are company-reported and not independently validated in the available data.

Short descriptiontext

Risklick AG is a Swiss AI company building Protocol AI, an enterprise SaaS platform that uses generative AI and an 800,000-trial database to accelerate clinical trial protocol design and authoring for pharmaceutical sponsors and life sciences companies.

Operating statusenum
Operating
Ownership categoryenum
Headcount rangeband
11–50
akta.pro rankint
HeadquartersBern, Switzerland
HQ citystring
Bern
HQ countrystring
Switzerland
HQ regionstring
Europe
Markets served

Serves global market

Offices1 record

Each record includes

City, Country, Type, Description, Source

Keyword5 values
clinical trial protocols, AI protocol authoring, clinical trial design, protocol optimization software, evidence-based study design
Industry3 codes
PRIMARYHLAGAJAO
AI/ML Platforms for Drug Discovery & Experiment Optimization
Healthcare & Life Sciences/Life Science Tools & Services (CRO/CDMO/Lab Services)/Life Science Software & Informatics (LIMS/ELN/Bioinformatics)
SECONDARYHLACAOAC
Randomization & Trial Supply Management (RTSM/IRT/IVRS/IWRS)
Healthcare & Life Sciences/Digital Health & Health IT/Clinical Trials & Research Informatics (eCOA/ePRO/EDC)
SECONDARYHLACAOAJ
Site & Investigator Platforms (Site Payments, Feasibility, Activation)
Healthcare & Life Sciences/Digital Health & Health IT/Clinical Trials & Research Informatics (eCOA/ePRO/EDC)
NAICS code1 code
  • Software Publishers5132
SIC code1 code
  • Services-Prepackaged Software7372
Product category
Clinical Trial Protocol Development Software
Social media profiles2 records
GTM motion1 record

Each record includes

Type, Description, Source

Revenue model1 record
1Protocol AI SaaS Subscription
TypeSubscription Recurring
Description

Subscription-based access to the Protocol AI software platform delivered as a SaaS solution. Access is tiered by user roles (Organization Admin, Creator, Reviewer, Reader) and governed by subscription plans specifying usage limits, feature access, and contract terms. Fees are due in advance and non-refundable upon termination.

risklick.ch
Marketing channels4 records

Each record includes

Title, Type, Stage, Description, Source

Distribution channels3 records

Each record includes

Title, Type, Scope, Target buyer, Description, Source

Cost components5 values
Technology or R&D, Personnel, Infrastructure, Marketing or Sales, Operations
Pricing details1 tier
1Subscription-based access with tiered user roles and feature access
ModelSubscriptionBilling cadenceAnnual
Notes

Subscription plans define user roles (Organization Admin, Creator, Reviewer, Reader), feature access, usage limits (number of users, duration, features), and contract duration. Fees are due in advance and non-refundable upon termination.

risklick.ch
GTM typeB2B
B2B
Offering typeSoftware
Software
Brand1 of 2 records shown
1Protocol AI
Description

AI-powered end-to-end software solution for designing and developing clinical trial protocols and study plans rapidly and efficiently.

risklick.ch
+1 more record
Core offering1 text field

Risklick develops and sells Protocol AI, an end-to-end SaaS platform that uses customized generative AI and a proprietary database of over 800,000 clinical trials to enable pharmaceutical sponsors and life sciences companies to design, optimize, and generate clinical trial protocols and study plans. The platform supports a three-step Explore-Design-Develop workflow, produces ICH M11/USDM-standard digital protocols, and integrates with EDC and eTMF systems, reducing protocol development time by 50%, amendments by 20%, and implementation time by 40%.

Differentiator
Functional benefit
Problem solved
Quantifiable outcome1 of 4 values shown
  • 50% reduction in protocol and study plan development time
+3 more records
Product overview1 text field

Risklick offers Protocol AI as its core flagship platform—an end-to-end AI solution for clinical trial protocol development—and maintains a separate product called Deduklick for automated data deduplication. Protocol AI is a unified platform that combines evidence-based study design exploration, multi-scenario optimization, and AI-powered protocol generation, all supported by a proprietary database of over 800,000 clinical trials. The platform supports digital protocol exports in ICH M11 and USDM standards, integrates with EDC and eTMF systems, and aims to reduce clinical development timelines significantly.

Product and service2 records
1Protocol AI
CategoryClinical Trial Protocol Development Software
Description

End-to-end AI-powered SaaS platform for designing and developing high-quality clinical trial protocols and study plans rapidly. It runs a 3-step Explore-Design-Develop workflow over a proprietary database of 800,000+ clinical trials, uses customized generative AI to author protocols, and exports ICH M11 and USDM-standard digital protocols with integration to EDC and eTMF systems. Sold via subscription to pharmaceutical sponsors and life sciences organizations.

2Deduklick
CategoryData Deduplication Software
Description

Transparent, fully automated AI-powered deduplication solution for removing duplicate records. Claimed to be 100x faster, 10x cheaper, and 100% precise compared to manual deduplication. Offered as a separate product alongside Protocol AI.

Scale indicator3 records

Each record includes

Type, Value, Description, Source

Partnership6 partners
Strategic tierCoreTypeStrategic or Co-development PartnerAnnounced on2026-01-13
Description

Citeline, a clinical solutions provider for the life sciences industry, partnered with Risklick to create an integrated AI-driven solution spanning protocol design, operationalization, and regulatory disclosure. The partnership addresses rising protocol amendment costs (each ranging from $140,000 to $500,000) by combining Risklick's protocol design expertise with Citeline's data and AI capabilities for evidence-based endpoint optimization. The combined solution enables sponsors to move from concept to execution faster and improve enrollment outcomes.

Strategic tierMinorTypeOthers
Description

Listed as a partner logo on the Risklick website under the 'Partners' section, indicating some form of collaborative relationship supporting Risklick's AI-driven clinical trial protocol development solutions.

3Siteminsel
Strategic tierMinorTypeOthers
Description

Listed as a partner logo on the Risklick website under the 'Partners' section, indicating some form of collaborative relationship supporting Risklick's AI-driven clinical trial protocol development solutions.

risklick.ch
Strategic tierMinorTypeOthers
Description

Listed as a partner logo on the Risklick website under the 'Partners' section, indicating collaboration with academia supporting Risklick's AI-driven clinical trial protocol development.

Strategic tierMinorTypeOthers
Description

Listed as a partner logo on the Risklick website under the 'Partners' section, indicating collaboration with academia supporting Risklick's AI-driven clinical trial protocol development.

6Debio (Swiss Biotech Association)
Strategic tierMinorTypeOthers
Description

Listed as a partner logo on the Risklick website under the 'Partners' section. Debio is the Swiss Biotech Association, indicating Risklick's membership and participation in the Swiss biotech ecosystem.

risklick.ch
Recent move5 records

Each record includes

Date, Type, Title, Description, Source

Expansion highlight6 records

Each record includes

Type, Description

Peers10 records
TypeEmerging player
Description

4G Clinical provides randomization and trial supply management (RTSM/IRT) and related clinical trial technology, serving the same pharma and CRO buyers that Risklick targets for protocol design workflows.

TypeBroad incumbent
Description

Veeva is the dominant cloud software provider for life sciences, including Veeva Vault EDC and CTMS. It targets the same pharma sponsors as Risklick and could build or acquire native AI protocol-design capabilities, making it the primary incumbent competitive threat to Protocol AI.

TypeBroad incumbent
Description

Medidata's Rave platform is a leading EDC and clinical trial technology suite used by global pharma sponsors. It serves the same protocol authoring and trial design workflows that Risklick targets and has been actively adding AI features across its clinical cloud.

4Oracle Health Clinical One
TypeBroad incumbent
Description

Oracle's Clinical One platform unifies EDC, RTSM, and trial design into a single cloud platform. As a broader clinical trials incumbent with deep enterprise pharma relationships, it competes for the protocol authoring and study design workflow that Protocol AI addresses.

TypeDirect peer
Description

Castor offers an AI-enabled EDC and eClinical platform used by sponsors and CROs for clinical trial design and data capture. It directly overlaps Risklick's protocol and trial design automation use cases, particularly for mid-sized sponsors and academic trials.

TypeEmerging player
Description

Saama provides AI-driven clinical development analytics and automation for pharma, including protocol design and patient journey insights. It overlaps with Risklick's evidence-based protocol optimization focus, targeting the same pharma sponsors.

7Deep 6 AI
TypeEmerging player
Description

Deep 6 AI uses AI on structured and unstructured clinical data to accelerate trial feasibility, patient recruitment, and protocol design. It is an emerging player targeting adjacent parts of the clinical trial workflow that Risklick also addresses.

TypeBroad incumbent
Description

IQVIA is the world's largest CRO and a major clinical technology provider, with AI-enabled trial design and real-world data assets. It competes broadly with Risklick for pharma sponsor spend on protocol design and clinical development optimization.

TypeEmerging player
Description

Medable is a decentralized clinical trial platform that incorporates AI-enabled study design and protocol authoring workflows for sponsors and CROs. It targets a similar customer base as Risklick with overlapping protocol automation capabilities.

TypeEmerging player
Description

Y Prime provides eClinical solutions including EDC, IRT, and increasingly AI-enabled protocol authoring tools for pharma and biotech sponsors. It is a closer-sized competitor to Risklick in clinical trial design automation.

Market position
Strengths2 records

Each record includes

Headline, Details, Source

Weaknesses5 records

Each record includes

Headline, Details, Source

Competitive moat5 records

Each record includes

Type, Details

Key risks6 records

Each record includes

Headline, Details, Source

Key highlights7 records

Each record includes

Headline, Details, Source

Customer concentration

Classification, Details

Segment2 records

Each record includes

Title, Type, Primary, Description, Pain point addressed, Use case, Source

Ideal customer profile2 records

Each record includes

Profile, Firmographic size, Sales motion, Sales cycle length, Buying structure, Purchase trigger, Buyer persona, Geography, Industry vertical, Primary use case, Description, Pain points, Evidence proof points, Target buyer

Technology focused
Yes
API detail
Has APIbool
No

Docs URL, Description

Integration2 records

Each record includes

Title, Type, Description, Source

AI capability6 records

Each record includes

Type, Description, Source

AI maturity
App detail

Has app

Feature6 records

Each record includes

Title, Differentiator, Description, Source

Core technology
Revenue estimate
Valuation estimate
Number of profiles
Profiles4 records

Each record includes

Name, Designation, Designation category, Overview, Profile commentary, Source

No data
Compliance3 records

Each record includes

Name, Class, Description

Funding overview

Funding stage, Last funding date, Total funding USD

Funding rounds1 record

Each record includes

Round, Amount USD, Date, Pre money valuation, Total investors, Investors, News

Investors1 record

Each record includes

Name, Type, Date of entry, Rounds participated, Website

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

M&A

Each record includes

Name, Acquisition type, Announced date, Completed date, Status, Website, News

Investment

Each record includes

Name, Round, Announced date, Lead investor, Website, News

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Risklick

Clinical Trial Protocol Development Softwarerisklick.ch

Risklick AG is a Swiss AI company building Protocol AI, an enterprise SaaS platform that uses generative AI and an 800,000-trial database to accelerate clinical trial protocol design and authoring for pharmaceutical sponsors and life sciences companies.

What Risklick does

Risklick AG is a Swiss AI company founded in 2019 and headquartered in Bern that develops Protocol AI, an enterprise SaaS platform for designing and authoring clinical trial protocols and study plans. The platform is powered by a proprietary database of over 800,000 clinical trials linked to publications, regulatory approvals, and safety data, and uses customized generative AI to produce protocols in ICH M11 and USDM-standard digital formats with export options for Word, Excel, or JSON. It integrates directly with EDC and eTMF systems and follows a structured three-step workflow (Explore, Design, Develop) for evidence-based study design optimization.

The company targets pharmaceutical sponsors as its primary segment and life sciences organizations (CROs and biotech companies) as a secondary segment, selling through enterprise direct sales with "Request a Demo" CTAs and annual subscription plans with tiered user roles (Organization Admin, Creator, Reviewer, Reader). Pricing is quote-based and not publicly disclosed. A secondary product, Deduklick, offers AI-powered automated data deduplication as an add-on. Strategic distribution is augmented by a January 2026 partnership with Citeline, and the company holds ISO 27001:2022 certification and GDPR compliance posture.

Risklick is privately held, backed by Debiopharm Innovation Fund since April 2024, and has received the Innosuisse Certificate recognizing growth readiness in the second half of 2025. Stated outcome metrics include a 50% reduction in protocol development time, 20% reduction in protocol amendments, and 40% reduction in protocol implementation time, though these figures are company-reported and not independently validated in the available data.

Risklick firmographics

Firmographics
Name
Risklick
Legal name
Risklick AG
Website
https://risklick.ch
Company type
Private
Founded year
2019
Operating status
Operating
Headcount range
11–50 employees
Short description
Risklick AG is a Swiss AI company building Protocol AI, an enterprise SaaS platform that uses generative AI and an 800,000-trial database to accelerate clinical trial protocol design and authoring for pharmaceutical sponsors and life sciences companies.
Ownership category
akta.pro rank

Risklick industry classification

Industry
Product category
Clinical Trial Protocol Development Software
NAICS
Software Publishers (5132)
SIC
Services-Prepackaged Software (7372)
akta.pro industry
PRIMARYHLAGAJAO
AI/ML Platforms for Drug Discovery & Experiment Optimization
Healthcare & Life Sciences/Life Science Tools & Services (CRO/CDMO/Lab Services)/Life Science Software & Informatics (LIMS/ELN/Bioinformatics)
SECONDARYHLACAOAC
Randomization & Trial Supply Management (RTSM/IRT/IVRS/IWRS)
Healthcare & Life Sciences/Digital Health & Health IT/Clinical Trials & Research Informatics (eCOA/ePRO/EDC)
SECONDARYHLACAOAJ
Site & Investigator Platforms (Site Payments, Feasibility, Activation)
Healthcare & Life Sciences/Digital Health & Health IT/Clinical Trials & Research Informatics (eCOA/ePRO/EDC)

Keywords

  • Clinical trial protocols
  • AI protocol authoring
  • Clinical trial design
  • Protocol optimization software
  • Evidence-based study design

Where Risklick is headquartered

Location

Headquarters

HQ city
Bern
HQ country
Switzerland
HQ region
Europe

Offices1 record

Markets served

Risklick business model

Business model
GTM type
B2B
Offering type
Software
Cost components
Technology or R&D, Personnel, Infrastructure, Marketing or Sales, Operations

Revenue model

  1. Protocol AI SaaS Subscription: Subscription-based access to the Protocol AI software platform delivered as a SaaS solution. Access is tiered by user roles (Organization Admin, Creator, Reviewer, Reader) and governed by subscription plans specifying usage limits, feature access, and contract terms. Fees are due in advance and non-refundable upon termination.

Pricing tiers

ModelBillingPrice
SubscriptionAnnualSubscription-based access with tiered user roles and feature access

Go-to-market motion1 record

Distribution channels3 records

Marketing channels4 records

Risklick product offering

Product offering

Core offering

Risklick develops and sells Protocol AI, an end-to-end SaaS platform that uses customized generative AI and a proprietary database of over 800,000 clinical trials to enable pharmaceutical sponsors and life sciences companies to design, optimize, and generate clinical trial protocols and study plans. The platform supports a three-step Explore-Design-Develop workflow, produces ICH M11/USDM-standard digital protocols, and integrates with EDC and eTMF systems, reducing protocol development time by 50%, amendments by 20%, and implementation time by 40%.

Product overview

Risklick offers Protocol AI as its core flagship platform—an end-to-end AI solution for clinical trial protocol development—and maintains a separate product called Deduklick for automated data deduplication. Protocol AI is a unified platform that combines evidence-based study design exploration, multi-scenario optimization, and AI-powered protocol generation, all supported by a proprietary database of over 800,000 clinical trials. The platform supports digital protocol exports in ICH M11 and USDM standards, integrates with EDC and eTMF systems, and aims to reduce clinical development timelines significantly.

Differentiator

Problem solved

Functional benefit

Brands

  • Protocol AI: AI-powered end-to-end software solution for designing and developing clinical trial protocols and study plans rapidly and efficiently.
  • Deduklick

Products and services

  • Protocol AI End-to-end AI-powered SaaS platform for designing and developing high-quality clinical trial protocols and study plans rapidly. It runs a 3-step Explore-Design-Develop workflow over a proprietary database of 800,000+ clinical trials, uses customized generative AI to author protocols, and exports ICH M11 and USDM-standard digital protocols with integration to EDC and eTMF systems. Sold via subscription to pharmaceutical sponsors and life sciences organizations.
  • Deduklick Transparent, fully automated AI-powered deduplication solution for removing duplicate records. Claimed to be 100x faster, 10x cheaper, and 100% precise compared to manual deduplication. Offered as a separate product alongside Protocol AI.

Quantifiable outcome

  • 50% reduction in protocol and study plan development time
  • +3 more outcomes

Companies that use Risklick

Customer profile

Segments2 records

Ideal customer profiles2 records

Risklick technology and API

Technology

Technology focussed Yes

API detail

Has API
No
API docs
API detail

Core technology

AI maturity

App detail

Integration2 records

AI capability6 records

Feature6 records

Risklick partnerships and signals

Strategic signal

Partnerships

Six partnerships are on record, tiered core and minor.

  • CitelinecoreStrategic or Co-development Partner · 13 January 2026Citeline, a clinical solutions provider for the life sciences industry, partnered with Risklick to create an integrated AI-driven solution spanning protocol design, operationalization, and regulatory disclosure. The partnership addresses rising protocol amendment costs (each ranging from $140,000 to $500,000) by combining Risklick's protocol design expertise with Citeline's data and AI capabilities for evidence-based endpoint optimization. The combined solution enables sponsors to move from concept to execution faster and improve enrollment outcomes.
  • be-advancedminorOthersListed as a partner logo on the Risklick website under the 'Partners' section, indicating some form of collaborative relationship supporting Risklick's AI-driven clinical trial protocol development solutions.
  • SiteminselminorOthersListed as a partner logo on the Risklick website under the 'Partners' section, indicating some form of collaborative relationship supporting Risklick's AI-driven clinical trial protocol development solutions.
  • University of Geneva (UNIGE)minorOthersListed as a partner logo on the Risklick website under the 'Partners' section, indicating collaboration with academia supporting Risklick's AI-driven clinical trial protocol development.
  • University of Bern (UNIBE)minorOthersListed as a partner logo on the Risklick website under the 'Partners' section, indicating collaboration with academia supporting Risklick's AI-driven clinical trial protocol development.
  • Debio (Swiss Biotech Association)minorOthersListed as a partner logo on the Risklick website under the 'Partners' section. Debio is the Swiss Biotech Association, indicating Risklick's membership and participation in the Swiss biotech ecosystem.

Scale indicators3 records

Recent moves5 records

Expansion highlights6 records

Risklick competitors and assessment

Company assessment

Emerging players

  • 4G Clinical: 4G Clinical provides randomization and trial supply management (RTSM/IRT) and related clinical trial technology, serving the same pharma and CRO buyers that Risklick targets for protocol design workflows.
  • Saama Technologies: Saama provides AI-driven clinical development analytics and automation for pharma, including protocol design and patient journey insights. It overlaps with Risklick's evidence-based protocol optimization focus, targeting the same pharma sponsors.
  • Deep 6 AI: Deep 6 AI uses AI on structured and unstructured clinical data to accelerate trial feasibility, patient recruitment, and protocol design. It is an emerging player targeting adjacent parts of the clinical trial workflow that Risklick also addresses.
  • Medable: Medable is a decentralized clinical trial platform that incorporates AI-enabled study design and protocol authoring workflows for sponsors and CROs. It targets a similar customer base as Risklick with overlapping protocol automation capabilities.
  • Y Prime: Y Prime provides eClinical solutions including EDC, IRT, and increasingly AI-enabled protocol authoring tools for pharma and biotech sponsors. It is a closer-sized competitor to Risklick in clinical trial design automation.

Broad incumbents

  • Veeva Systems: Veeva is the dominant cloud software provider for life sciences, including Veeva Vault EDC and CTMS. It targets the same pharma sponsors as Risklick and could build or acquire native AI protocol-design capabilities, making it the primary incumbent competitive threat to Protocol AI.
  • Medidata Solutions (Dassault Systèmes): Medidata's Rave platform is a leading EDC and clinical trial technology suite used by global pharma sponsors. It serves the same protocol authoring and trial design workflows that Risklick targets and has been actively adding AI features across its clinical cloud.
  • Oracle Health Clinical One: Oracle's Clinical One platform unifies EDC, RTSM, and trial design into a single cloud platform. As a broader clinical trials incumbent with deep enterprise pharma relationships, it competes for the protocol authoring and study design workflow that Protocol AI addresses.
  • IQVIA: IQVIA is the world's largest CRO and a major clinical technology provider, with AI-enabled trial design and real-world data assets. It competes broadly with Risklick for pharma sponsor spend on protocol design and clinical development optimization.

Direct peers

  • Castor: Castor offers an AI-enabled EDC and eClinical platform used by sponsors and CROs for clinical trial design and data capture. It directly overlaps Risklick's protocol and trial design automation use cases, particularly for mid-sized sponsors and academic trials.

Market position

Strengths2 records

Weaknesses5 records

Competitive moat5 records

Key risks6 records

Key highlights7 records

Customer concentration

Risklick social profiles

Digital presence

Risklick compliance and trust

Trust signal

Compliance3 records

Risklick financial estimates

Financial estimate

Revenue estimate

Valuation estimate

Risklick leadership team

Management profile

Number of profiles

Profiles4 records

Risklick funding detail

Funding detail

Funding overview

Funding rounds1 record

Investors1 record

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

Risklick M&A and investment

M&A and investment

M&A

Investments

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Frequently asked questions about Risklick

What does Risklick do?

Risklick develops and sells Protocol AI, an end-to-end SaaS platform that uses customized generative AI and a proprietary database of over 800,000 clinical trials to enable pharmaceutical sponsors and life sciences companies to design, optimize, and generate clinical trial protocols and study plans. The platform supports a three-step Explore-Design-Develop workflow, produces ICH M11/USDM-standard digital protocols, and integrates with EDC and eTMF systems, reducing protocol development time by 50%, amendments by 20%, and implementation time by 40%.

Is Risklick a public or private company?

Risklick is a private company. It is classified as venture growth investor backed and is currently operating.

When was Risklick founded?

Risklick was founded in 2019. It employs 11 to 50 people.

Where is Risklick based?

Risklick is headquartered in Bern, Switzerland, in the Europe region.

How does Risklick make money?

One revenue line is on record: protocol AI SaaS Subscription.

Who are Risklick's main competitors?

Emerging players on record are 4G Clinical, Saama Technologies, Deep 6 AI, Medable and Y Prime. Broad incumbents are Veeva Systems, Medidata Solutions (Dassault Systèmes), Oracle Health Clinical One and IQVIA. Castor is listed as a direct peer.

Does Risklick have an API?

No public API is recorded for Risklick.

What industry is Risklick in?

Risklick's product category is Clinical Trial Protocol Development Software. Its primary akta.pro industry code is HLAGAJAO, AI/ML Platforms for Drug Discovery & Experiment Optimization, with a secondary code of HLACAOAC, Randomization & Trial Supply Management (RTSM/IRT/IVRS/IWRS). Its NAICS code is 5132 and its SIC code is 7372.

Unlock the full company data

50 free credits on sign-up, no credit card required.

Contact sales
Live signals
In Vivorisklick-partnershipCiteline and Risklick partnered to develop an integrated protocol development solution spanning design, authoring, operationalization, and regulatory disclosure. Protocol amendments have risen since 2015, costing $140,000 to $500,000 each, prompting the need for AI-driven optimization. The companies aim to digitize the entire protocol development process.SWI swissinfo.chAI’s next pharma challenge: tackling costly and risky clinical trialsPharmaceutical companies are increasingly deploying AI technologies to address the slow, expensive, and failure-prone clinical trial process, which consumes 60-70% of the decade-long, $1-2 billion drug development timeline and sees approximately 90% of drug candidates fail during human testing. The FDA announced an April pilot program to assess AI-enabled technologies for improving early-phase clinical trials, while companies including Swiss-based Novartis, Risklick, SOPHiA GENETICS, and US-based Unlearn are developing AI tools for protocol writing, patient recruitment, and digital twin simulations to reduce trial timelines and costs.MacaubusinessCiteline-Risklick Partnership Creates Smarter Protocols, from Design to OptimizationCiteline, a life sciences clinical solutions provider, and Swiss AI firm Risklick announced a partnership on Jan. 13, 2026 to build an integrated protocol development platform spanning design, authoring, operationalization and regulatory disclosure. Protocol amendments have risen since 2015, with single amendments costing $140,000 to $500,000. Citeline and Risklick did not disclose financial terms.GlobeNewswireCiteline-Risklick Partnership Creates Smarter Protocols, from Design to OptimizationCiteline, a clinical solutions provider for the life sciences industry, has partnered with Risklick, a Swiss AI company specializing in clinical trial protocol development, to create an integrated solution spanning protocol design, operationalization, and regulatory disclosure. The partnership addresses the rising costs of protocol amendments, which industry studies show have increased substantially since 2015, with each amendment costing between $140,000 and $500,000. The combined solution leverages Citeline's data and AI for evidence-based optimization of protocol endpoints and Risklick's purpose-built AI platform to enable pharmaceutical sponsors to reduce risk, accelerate timelines, and improve enrollment outcomes.In VivoCiteline-Risklick Partnership | CitelineCiteline and Risklick partnered to develop an AI-driven protocol development solution spanning design, operationalization, and regulatory disclosure. Protocol amendments have risen since 2015, costing $140,000 to $500,000 each, prompting the need for smarter design. The companies aim to digitize the entire protocol development process.TmcnetSwiss startup Risklick launches AI-based software for medical device clinical trialsRisklick, a University of Bern spin-off, launched Protocol AI, AI software for medical device clinical trials. It uses NLP and ML to draft protocols, claiming a 50% reduction in study document development time. The company expects similar savings for medical devices.PR NewswireSwiss startup Risklick launches AI-based software for medical device clinical trialsSwiss startup Risklick launched Protocol AI, an AI-based software for medical device clinical trials. The software uses NLP and ML to draft protocols, claiming a 50% reduction in study document development time. It aims to accelerate patient access to new medical devices.PR NewswireSwiss startup Risklick launches AI-based software for medical device clinical trialsSwiss startup Risklick launched Protocol AI, an AI-based software for medical device clinical trials. The software uses NLP and machine learning to draft protocols, claiming a 50% reduction in study document development time. It aims to accelerate patient access to new medical devices.YahooSwiss startup Risklick launches AI-based software for medical device clinical trialsRisklick, a University of Bern spin-off, launched Protocol AI, AI software for medical device clinical trials. It uses NLP and ML to draft protocols, claiming a 50% reduction in study document development time. The company expects similar savings for medical devices.